Literature DB >> 12476954

Strategies for the identification of inhibitors of West Nile virus and other flaviviruses.

Pei-Yong Shi1.   

Abstract

The recent outbreaks of West Nile virus (WNV) and other emerging and re-emerging flaviviruses, have made prevention and treatment of flavivirus infections a global public health priority. No inhibitor is currently available for use as an antiflavivirus therapy. In this communication, I review (i) stages of flavivirus replication representing potential targets for antiviral drug discovery; (ii) strategies for identification of flavivirus inhibitors; and (iii) existing antiviral inhibitors reported to have anti-WNV or other antiflavivirus activities. Flaviviruses share conserved nucleotide elements and amino acid sequences, and have similar genome organization and replication strategies. As such, it is hoped that broad spectrum flavivirus inhibitors could be identified through screening of compound libraries.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12476954

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN: 1472-4472


  7 in total

1.  Structure and function of the 3' terminal six nucleotides of the west nile virus genome in viral replication.

Authors:  Mark Tilgner; Pei-Yong Shi
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

2.  Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication.

Authors:  Tia S Deas; Iwona Binduga-Gajewska; Mark Tilgner; Ping Ren; David A Stein; Hong M Moulton; Patrick L Iversen; Elizabeth B Kauffman; Laura D Kramer; Pei-Yong Shi
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

3.  Potential high-throughput assay for screening inhibitors of West Nile virus replication.

Authors:  Michael K Lo; Mark Tilgner; Pei-Yong Shi
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

4.  Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade.

Authors:  Sharmila Nair; Luciano Mazzoccoli; Arijita Jash; Jennifer Govero; Sachendra S Bais; Tong Hu; Camila R Fontes-Garfias; Chao Shan; Hideho Okada; Sujan Shresta; Jeremy N Rich; Pei-Yong Shi; Michael S Diamond; Milan G Chheda
Journal:  JCI Insight       Date:  2021-01-11

5.  N-methylisatin-beta-thiosemicarbazone derivative (SCH 16) is an inhibitor of Japanese encephalitis virus infection in vitro and in vivo.

Authors:  Liba Sebastian; Anita Desai; Madhusudana N Shampur; Yogeeswari Perumal; D Sriram; Ravi Vasanthapuram
Journal:  Virol J       Date:  2008-05-22       Impact factor: 4.099

6.  Identification of three antiviral inhibitors against Japanese encephalitis virus from library of pharmacologically active compounds 1280.

Authors:  Jin'e Fang; Leqiang Sun; Guiqing Peng; Jia Xu; Rui Zhou; Shengbo Cao; Huanchun Chen; Yunfeng Song
Journal:  PLoS One       Date:  2013-11-04       Impact factor: 3.240

7.  Zika Virus Replicons for Drug Discovery.

Authors:  Xuping Xie; Jing Zou; Chao Shan; Yujiao Yang; Dieudonné Buh Kum; Kai Dallmeier; Johan Neyts; Pei-Yong Shi
Journal:  EBioMedicine       Date:  2016-09-14       Impact factor: 8.143

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.